MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.9 EUR
-0.02 (-0.51%)
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 30 industry peers in the Health Care Providers & Services industry. While MED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MED scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
- MED had positive earnings in the past year.
- MED had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
- Each year in the past 5 years MED had a positive operating cash flow.
1.2 Ratios
- MED has a better Return On Assets (3.85%) than 73.33% of its industry peers.
- MED's Return On Equity of 14.15% is fine compared to the rest of the industry. MED outperforms 73.33% of its industry peers.
- MED has a Return On Invested Capital of 7.06%. This is in the better half of the industry: MED outperforms 70.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 6.46%.
- The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
- MED has a Profit Margin of 4.40%. This is in the better half of the industry: MED outperforms 76.67% of its industry peers.
- In the last couple of years the Profit Margin of MED has grown nicely.
- The Operating Margin of MED (8.52%) is better than 76.67% of its industry peers.
- MED's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 84.08%, MED belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
- MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
- Compared to 1 year ago, MED has about the same amount of shares outstanding.
- The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
- Compared to 1 year ago, MED has an improved debt to assets ratio.
2.2 Solvency
- MED has an Altman-Z score of 1.60. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of MED (1.60) is worse than 66.67% of its industry peers.
- The Debt to FCF ratio of MED is 9.63, which is on the high side as it means it would take MED, 9.63 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 9.63, MED is in line with its industry, outperforming 56.67% of the companies in the same industry.
- A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
- MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 63.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.6 |
ROIC/WACC1.4
WACC5.03%
2.3 Liquidity
- MED has a Current Ratio of 1.93. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
- MED has a better Current ratio (1.93) than 86.67% of its industry peers.
- MED has a Quick Ratio of 1.89. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
- MED's Quick ratio of 1.89 is amongst the best of the industry. MED outperforms 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 414.18% over the past year.
- MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
- MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
- The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
- Based on estimates for the next years, MED will show a very strong growth in Earnings Per Share. The EPS will grow by 20.09% on average per year.
- Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 3.42% on average per year.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.27 indicates a rather cheap valuation of MED.
- Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.30. MED is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 5.72, the valuation of MED can be described as very cheap.
- 100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.32. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.27 | ||
| Fwd PE | 5.72 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 96.67% of the companies in the same industry.
- MED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MED is cheaper than 86.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.98 | ||
| EV/EBITDA | 2.96 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MED may justify a higher PE ratio.
- MED's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.25
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
- MED has a Yearly Dividend Yield of 1.05%. Purely for dividend investing, there may be better candidates out there.
- MED's Dividend Yield is comparable with the industry average which is at 1.73.
- With a Dividend Yield of 1.05, MED pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.05% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.27 and the Price/Book (PB) ratio is 0.75.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.